Which antiplatelet agent? The debate intensifies
05:04 EDT 8 Jun 2012 | GaBI online
Plavix (clopidogrel) has been a blockbuster drug. The lower cost of generic clopidogrel, available for the first time since 17 May 2012 [1], is intensifying debate among cardiologists over how to make sure patients get optimal benefit from any blood-..
Original Article: Which antiplatelet agent? The debate intensifies
More From BioPortfolio on "Which antiplatelet agent? The debate intensifies"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
